Zenas BioPharma (ZBIO) Other Working Capital Changes (2023 - 2026)

Zenas BioPharma's Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$211000.0 for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 4.95% year-over-year to -$211000.0 in Q1 2026; TTM through Mar 2026 was -$891000.0, a 21.89% decrease from a year earlier, with the FY2025 full-year figure at -$902000.0, down 34.03% from the prior year.
• Other Working Capital Changes improved to -$211000.0 in Q1 2026 per ZBIO's latest filing, from -$245000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $8.2 million in Q4 2024 and bottomed at -$1.8 million in Q3 2024.
• The 4-year median for Other Working Capital Changes is $977000.0 (2025), against an average of $1.6 million.
• Across the five-year window, Other Working Capital Changes slumped 70.16% in 2025 and advanced 4.95% in 2026, its largest moves.
• Year by year, Other Working Capital Changes stood at -$151000.0 in 2023, then tumbled by 61.59% to -$244000.0 in 2024, then retreated by 0.41% to -$245000.0 in 2025, then grew by 13.88% to -$211000.0 in 2026.
• Per Business Quant, the three latest ZBIO Other Working Capital Changes figures stand at -$211000.0 (Q1 2026), -$245000.0 (Q4 2025), and -$211000.0 (Q3 2025).